Kura Oncology's Ziftomenib, Has Been Granted FDA Breakthrough Therapy Designation For Relapsed/Refractory NPM1-mutant Acute Myeloid Leukemia
Kura Oncology's Ziftomenib, Has Been Granted FDA Breakthrough Therapy Designation For Relapsed/Refractory NPM1-mutant Acute Myeloid Leukemia
Kura Oncology 的 Ziftomenib 已獲得 FDA 突變體復發/難治性 NPM1 突變體急性髓系白血病的突破性療法稱號
Kura Oncology's Ziftomenib, Has Been Granted FDA Breakthrough Therapy Designation For Relapsed/Refractory NPM1-mutant Acute Myeloid Leukemia
Kura Oncology 的 Ziftomenib 已獲得 FDA 突變體復發/難治性 NPM1 突變體急性髓系白血病的突破性療法稱號
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。